The synergy of Vitamin C with decitabine activates TET2 in leukemic cells and significantly improves overall survival in elderly patients with acute myeloid leukemia

Figueroa, 2010, DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia, Cancer Cell, 17, 13, 10.1016/j.ccr.2009.11.020

Kantarjian, 2012, Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia, J. Clin. Oncol., 30, 2670, 10.1200/JCO.2011.38.9429

Momparler, 2014, Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation, Clin. Epigenet., 6, 19, 10.1186/1868-7083-6-19

Li, 2015, Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia, Oncotarget, 6, 6448, 10.18632/oncotarget.3361

Huang, 2014, Connections between TET proteins and aberrant DNA modification in cancer, Trends Genet., 30, 464, 10.1016/j.tig.2014.07.005

Scopim-Ribeiro, 2016, Low Ten-eleven-translocation 2 (TET2) transcript level is independent of TET2 mutation in patients with myeloid neoplasms, Diagn. Pathol., 11, 28, 10.1186/s13000-016-0476-4

Bejar, 2014, TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients, Blood, 124, 2705, 10.1182/blood-2014-06-582809

Scopim-Ribeiro, 2015, Ten-Eleven-Translocation 2 (TET2) is downregulated in myelodysplastic syndromes, Eur. J. Haematol., 94, 413, 10.1111/ejh.12445

Ko, 2010, Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2, Nature, 468, 839, 10.1038/nature09586

Chowdhury, 2015, The hypomethylating agent Decitabine causes a paradoxical increase in 5-hydroxymethylcytosine in human leukemia cells, Sci. Rep., 5, 9281, 10.1038/srep09281

Blaschke, 2013, VitaminC induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells, Natrue, 500, 222, 10.1038/nature12362

Minor, 2013, Ascorbate induces ten-eleven translocation (Tet) methylcytosine dioxygenase-mediated generation of 5-hydroxymethylcytosine, J. Biol. Chem., 288, 13669, 10.1074/jbc.C113.464800

Ma, 2014, High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy, Sci. Transl. Med., 6, 222ra18, 10.1126/scitranslmed.3007154

Perrone, 2009, Ascorbic acid inhibits antitumor activity of bortezomib in vivo, Leukemia, 23, 1679, 10.1038/leu.2009.83

Heaney, 2008, Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs, Cancer Res., 68, 8031, 10.1158/0008-5472.CAN-08-1490

Verrax, 2009, Pharmacologic concentrations of ascorbate are achieved by parenteral administration and exhibit antitumoral effects, Free Radic. Biol. Med., 47, 32, 10.1016/j.freeradbiomed.2009.02.016

Cimmino, 2017, Restoration of TET2 function blocks aberrant self-renewal and leukemia progression, Cell, 170, 1079, 10.1016/j.cell.2017.07.032

Welch, 2011, Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study, Am. J. Hematol., 86, 796, 10.1002/ajh.22092

Kim, 2015, High-dose vitamin C injection to cancer patients may promote thrombosis through procoagulant activation of erythrocytes, Toxicol. Sci., 147, 350, 10.1093/toxsci/kfv133

Cheson, 2003, Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia, J. Clin. Oncol., 21, 4642, 10.1200/JCO.2003.04.036

Wongtrakoongate, 2015, Epigenetic therapy of cancer stem and progenitor cells by targeting DNA methylation machineries, World J. Stem Cells, 7, 137, 10.4252/wjsc.v7.i1.137

Klco, 2013, Genomic impact of transient low-dose decitabine treatment on primary AML cells, Blood, 121, 1633, 10.1182/blood-2012-09-459313

Jiang, 2015, The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients, Oncotarget, 6, 33612, 10.18632/oncotarget.5600

Zhu, 2017, Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen-mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia, Biol. Blood Marrow Transplant., 23, 830, 10.1016/j.bbmt.2017.01.085

Dickson, 2013, Ascorbate-induced generation of 5-hydroxymethylcytosine is unaffected by varying levels of iron and 2-oxoglutarate, Biochem. Biophys. Res. Commun., 439, 522, 10.1016/j.bbrc.2013.09.010

Wang, 2011, The effect of decitabine on megakaryocyte maturation and platelet release, Thromb. Haemost., 106, 337, 10.1160/TH10-11-0744

Jung, 2015, Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients, Oncotarget, 6, 16653, 10.18632/oncotarget.3914

Ruiz, 2015, Hydroxymethylcytosine and demethylation of the γ-globin gene promoter during erythroid differentiation, Epigenetics, 10, 397, 10.1080/15592294.2015.1039220